Onglyza Lawsuit

According to results of a study recently published by researchers from the U.K., patients who have diabetes may show a reduction in heart failure, heart disease, and all-cause mortality when treated with certain diabetes drugs, including gliptins like . However, this study has not convinced many doctors that the previous links established between Onglyza and failure are invalid and this drug will likely continue to be prescribed with caution.

Study says Onglyza may Lower Heart Failure Risk in Diabetics, Doctors still have Doubts | Onglyza Lawsuit News Find out why some doctors are doubting a newly reported heart benefit associated with Onglyza. Has this drug harmed you?

A husband and wife filed an heart attack against the makers of the drug after the husband suffered a which he claims was caused by the drug. The lawsuit further claims that the drug makers knew about this risk and failed to warn its patients.

Husband and Wife File Onglyza Heart Attack Lawsuit | Onglyza Lawsuit News An Onglyza heart attack lawsuit was filed by a man who suffered a heart attack after taking the type 2 diabetes medication and claims that the drug makers failed to warn about this known risk. Read more here.

The type 2 drug may not increase the risk of , despite previous warnings, according to a recent analysis of clincal trials.

Study: Nesina May Not Increase Heart Attack Risk | Onglyza Lawsuit News A re-evaluation of Nesina clinical trials suggests that the type 2 diabetes drug might not increase the risk of heart failure, despite previous warnings. Read more here and contact our attorneys if you or a loved one has suffered heart failure while taking Nesina or the similar drug Onglyza.

In recent years, both of these types of diabetes drugs have been associated with an increased risk of a number of severe or even potentially fatal side effects. Onglyza and other DPP-4 inhibitors, also s as incretin mimetics, have been linked to a higher risk of serious including heart failure. In 2013, the publication of the SAVOR study in the New England Journal of Medicine raised concerns about Onglyza heart problems, and subsequent reviews of clinical trial data found that Onglyza patients may be at a higher risk for hospitalization for heart failure as well as all-cause mortality.

European Medicines Agency supports Onglyza/Farxiga Combination Drug | Onglyza Lawsuit News A new diabetes drug may soon hit the European market, but find out why the Onglyza combination was denied approval by the FDA.

On April 5, the FDA announced that all DPP-4 inhibitor drugs carrying the ingredients saxagliptin ( ) and alogliptin (Nesina) will now carry warnings of heart failure risks, which are especially high in patients who already have disease or kidney disease. Other drugs to which these new warnings will apply include Kombiglyze XR, Kazano, and Oseni, which are combinations of either saxagliptin or alogliptin and metformin or pioglitazone.

FDA issues new Onglyza Heart Risk Warnings | Onglyza Lawsuit News Find out why the FDA has added new Onglyza Heart Risk Warnings to labels. Important news for patients and their loved ones regarding the popular diabetes medication.

Onglyza and Kombiglyze rx, type 2 diabetes medication, has been found in recent studies to increase the risk of heart failure in patients.

Onglyza Heart Failure Lawyers | Miller Legal LLP Onglyza, a type 2 diabetes medication, has been found in recent studies to increase the risk of heart failure in patients. Contact our attorneys at 1-800-610-1281 for legal assistance if you or a loved one has been affected.

The U.S. Food and Drug Administration (FDA) is investigating a study linking Onglyza and Kombiglyze XR to a 27% increased risk of hospitalization for heart failure. Call Today: (888) 495-2876

The FDA has added a warning to diabetes drug stating that the diabetes drug may increase the risk of

FDA adds Diabetic Ketoacidosis, Infection Risks to Invokana Warning Labels | Diabetic... The FDA has added a warning label to diabetes drug Invokana stating that the drug may increase the risk of diabetic ketoacidosis.

New study is now linking drug to increased risk of

Study links Onglyza to Risk of Pancreatitis | Onglyza Lawsuit News A recent study from the U.K. shows that Onglyza patients may be at a higher risk of acute pancreatitis, in addition to an increased risk of heart failure. Read more here and contact our attorneys for legal guidance if you have been affected.

A woman is filing a alleging that her mother's death from was caused by the side effects of .

Chicago Woman files Onglyza Lawsuit after Death of Mother | Onglyza Lawsuit News A Chicago woman is filing a lawsuit claiming that her mother's death from heart failure was the result of the drug Onglyza. Learn more here.

Last month, a consumer advocacy group brought attention to serious and potentially fatal cardiac side effects including associated with the diabetes drug . Now, the drug is once again thrust into the spotlight as a leading pharmacy benefits company recently announced that they would no longer cover Onglyza for patients because of the linked to the potentially dangerous drug.

Express Scripts drops Onglyza because of Risks | Onglyza Lawsuit News Leading pharmacy Express Scripts drops diabetes medication Onglyza because of severe side effects, such as heart failure and pancreatic cancer.

A panel of FDA advisers has recommended that the agency mandate drug makers to warn of the increased risk of heart failure and death linked to the diabetes drug Onglyza. http://www.onglyzalawsuit.org/news/fda-advisors-call-for-onglyza-heart-failure-warning/

FDA Advisors call for Onglyza Heart Failure Warning | Onglyza Lawsuit News FDA releases information that the side effects of diabetes drug Onglyza may be linked to a higher rate of “all-cause

FDA says Onglyza Side Effects may cause Death | What every Onglyza patient and their loved ones need to know immediately. Did you know that Onglyza has been linked to potentially fatal side effects?